Europe Must Seize Opportunity For Change
Five Key Issues For EU Pharma Strategy Cited By Medicines For Europe
The EU’s upcoming pharma strategy offers an important opportunity for change, according to Medicines for Europe. The off-patent industry body has set out five key issues that should be priorities for the EU Commission.
You may also be interested in...
Medicines for Europe has highlighted the need for an improved digital strategy across the EU in order to improve patient information and access to medicines, among other benefits like reducing the risk of supply disruptions, especially in the context of the current pandemic.
Sen. Mike Lee, R-UT, has introduced draft legislation in the US that would stop the FDA from requiring biosimilars to conduct ‘unnecessary’ switching studies in order to obtain an interchangeability designation.
Stada has announced a change in management for its emerging markets division, with Sanofi’s Stéphane Jacqmin joining the firm from the start of 2023 to replace Carsten Cron, who is leaving the German generics and biosimilars giant for pastures new.